Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 10, 2021 16:30 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Presents Poster Demonstrating Functional Selectivity of Second Anti-NRP2 Antibody

Preclinical candidate is second to demonstrate selective blocking ability from in-house panel of antibodies targeting NRP2. aNRP2-14 blocks Semaphorin 3F/NRP2 signaling pathways which are...
May 25, 2021 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Strengthens Board of Directors with Appointment of Dr. Sara Zaknoen

SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
May 19, 2021 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Presents Preclinical Research Highlighting Mechanistic Insights into Tumor Inhibitory Effects of ATYR2810

SAN DIEGO, May 19, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
May 13, 2021 16:05 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces First Quarter 2021 Results and Provides Corporate Update

Data from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis expected in the third quarter. Preclinical data for IND candidate ATYR2810 showed anti-tumor effects in models of TNBC and...
May 12, 2021 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma and its Hong Kong Subsidiary, Pangu BioPharma, Achieve Milestones for First Year of Government Grant to Develop Bispecific Antibody Platform

SAN DIEGO, May 12, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
May 11, 2021 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Promotion of Leslie Nangle, Ph.D., to Vice President of Research

SAN DIEGO, May 11, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
May 06, 2021 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Webcast Conference Call Reporting First Quarter 2021 Financial Results

SAN DIEGO, May 06, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
April 20, 2021 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma and Foundation for Sarcoidosis Research Announce Town Hall Virtual Meeting on Steroids and Sarcoidosis

SAN DIEGO, April 20, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
April 14, 2021 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma and Lonza Announce Manufacturing Agreement for aTyr’s Anti-NRP2 Antibody ATYR2810

SAN DIEGO, April 14, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
April 09, 2021 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Presents Preclinical Research Showing Effects of ATYR2810 in Lung and Breast Cancer at the 2021 AACR Virtual Annual Meeting

Findings demonstrate tumor inhibitory effects of ATYR2810 when used as a monotherapy or in combination with chemotherapy in models of non-small cell lung cancer. ATYR2810 used in combination with...